Interview: MedPacto Sees Robust Prospects For ‘Best-In-Class’ ALK5 Inhibitor
Executive Summary
MedPacto is preparing for a critical Phase II US study with its potentially best-in-class ALK5 inhibitor, a potential rival to a Lilly molecule and that will be central to the South Korean bioventure’s long-term ambitions to become a global player.
You may also be interested in...
Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End
After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.